Market revenue in 2020 | USD 1,458.3 million |
Market revenue in 2028 | USD 2,770.7 million |
Growth rate | 8.4% (CAGR from 2020 to 2028) |
Largest segment | Reagent-based |
Fastest growing segment | Physical Disruption |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Reagent-based, Physical Disruption |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Bio-Rad Laboratories Inc, Roche Holding AG ADR, Qiagen NV, Danaher Corp, Miltenyi Biotec, IDEX Corp, BD, Claremont BioSolutions, Parr Instrument Company, Covaris, Cell Signaling Technology, Qsonica |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell lysis and disruption market will help companies and investors design strategic landscapes.
Reagent-based was the largest segment with a revenue share of 70.83% in 2020. Horizon Databook has segmented the U.S. cell lysis and disruption market based on reagent-based, physical disruption covering the revenue growth of each sub-segment from 2018 to 2028.
The cell lysis & disruption market in the U.S. is expected to grow significantly in the near future owing to recent developments in the molecular biology techniques within the country. The commercial production and sale of products that either are obtained from or use new biotechnology techniques is relatively recent.
Some of the noteworthy products in this regard include Amgen’s Blincyto, a biospecific antibody approved by FDA in 2018 and Novartis’s Zarxio, the first FDA-approved biosimilar in the U.S. Owing to the recent advancements.
There is a substantial rise in the sales of biotechnology products within the country and it is expected that the sales would increase by 10-fold in the next 10 years. Therefore, continuous innovations in the biotechnology sector are expected to provide lucrative growth opportunities to the U.S. cell lysis & disruption market over the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. cell lysis and disruption market , including forecasts for subscribers. This country databook contains high-level insights into U.S. cell lysis and disruption market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account